CYP2D6 rs5030866: Pharmacogenomics and *8 Variant
The genetic variant rs5030866 is a single-nucleotide polymorphism located in the CYP2D6 gene. It serves as the defining variant for the CYP2D6*8 haplotype, creating a premature stop codon that results in a completely nonfunctional enzyme. Individuals carrying this variant exhibit reduced or abolished capacity to metabolize medications cleared via the CYP2D6 pathway.
What each genotype means
| Genotype | What the research suggests | Reading |
|---|---|---|
| GG | You carry two reference functional alleles at this nucleotide position, which corresponds to the standard coding sequence. This result does not confer the *8 null defect, although your overall CYP2D6 metabolizer status still depends on other genetic variants across the gene. | Informational |
| GT | You carry one copy of the *8 loss-of-function allele alongside a standard allele at this locus. Depending on the genetic variant on your other chromosome, your body may process CYP2D6-metabolized medications more slowly than typical normal metabolizers. | Higher attention |
| TT | You carry two copies of the *8 nonsense variant, meaning both CYP2D6 alleles lack normal enzyme-producing capability. This genotype predicts a poor metabolizer status, significantly elevating the risk of drug accumulation or impaired prodrug activation. | Higher attention |
Genetic Architecture and the rs5030866 Variant
The rs5030866 variant is an exonic single-nucleotide substitution within the cytochrome P450 family 2 subfamily D member 6 (CYP2D6) gene, mapped to chromosome 22q13.2. Specifically annotated as c.505G>T (p.Gly169Ter or legacy G1758T), this mutation alters the coding sequence to introduce a premature termination codon. As a consequence, mRNA translation yields a truncated polypeptide lacking key catalytic domains, or the transcript undergoes nonsense-mediated decay. Within the standardized pharmacogene nomenclature curated by PharmVar, rs5030866 is the primary core marker defining the CYP2D6*8 star allele. Because the genetic variation directly prevents the synthesis of a functioning protein, it is classified functionally as a definitive null allele.
Biological Role of the CYP2D6 Enzyme
The CYP2D6 enzyme is an essential component of the hepatic cytochrome P450 monooxygenase system. Although accounting for only 2% to 4% of total hepatic CYP content, it contributes to the oxidative biotransformation and clearance of roughly 20% to 25% of all clinically prescribed medications. Its broad substrate catalog includes beta-blockers, antiarrhythmics, selective serotonin reuptake inhibitors, tricyclic antidepressants, typical and atypical antipsychotics, and certain opioids. In addition to eliminating drugs, CYP2D6 bioactivates prodrugs such as codeine and tramadol into their primary active analgesic metabolites, morphine and O-desmethyltramadol. Consequently, any alteration in CYP2D6 enzymatic capacity disrupts both medication clearance and active drug production.
Pharmacogenomic Evidence and Clinical Associations
Pharmacogenomic consortia, including the Clinical Pharmacogenetics Implementation Consortium (CPIC) and PharmGKB, assign the CYP2D6*8 allele an Activity Score of 0. When present alongside another nonfunctional allele (such as *3, *4, or *5), it establishes a Poor Metabolizer (PM) phenotype; when paired with a normal function allele (such as *1 or *2), it yields an Intermediate Metabolizer (IM) phenotype. Poor metabolizers clear standard substrates at severely reduced rates, elevating systemic drug concentrations and the hazard of dose-dependent adverse reactions, including tardive dyskinesia from antipsychotics or exaggerated cardiovascular effects from beta-blockers. Conversely, prodrugs fail to convert effectively, frequently leading to therapeutic failure. Because the allele is rare, statistical data from isolated single-variant prospective trials are limited, and recommendations are derived from pooled no-function allele models.
Frequency and Distribution Across Global Populations
The rs5030866 variant is considered rare worldwide. Reference genomic databases, including gnomAD and the CPIC global frequency repository, report that the minor T allele is identified almost exclusively at low frequencies in populations of European ancestry, generally falling below 0.5% (minor allele frequency < 0.005). In most East Asian, African, and Indigenous American demographic cohorts, the variant is exceptionally rare or practically absent. Because of its overall low prevalence, homozygous individuals (T/T) are seldom observed in population screenings, and the variant is usually detected as a heterozygous carrier state in broader multigene pharmacogenetic panels.
Clinical Utility and Next Steps for Patients
Understanding your rs5030866 genotype provides helpful insight into individual drug response traits, but it cannot be evaluated in isolation. A complete CYP2D6 metabolizer status requires comprehensive diplotype testing that accounts for both inherited alleles as well as structural copy number variations, such as full-gene deletions or duplications. Furthermore, nongenetic variables—including kidney and liver health, age, and drug-drug interactions involving CYP2D6 inhibitors—strongly dictate real-world metabolic clearance. Patients should never discontinue or modify prescribed medication dosages based on direct-to-consumer genetic findings. Any potential adjustments in therapeutic selection or dose titration must be reviewed directly with a licensed physician or clinical pharmacist.
How common is this variant?
The rs5030866 variant is rare across global populations, with a minor allele frequency typically below 0.005 (<0.5%) in individuals of European ancestry and virtually undetectable in most other ancestries.
Frequently asked questions
What is the relationship between rs5030866 and CYP2D6*8?
The rs5030866 variant is the defining genetic mutation for the CYP2D6*8 allele. It causes a nonsense mutation that terminates protein translation early, completely abolishing enzyme activity.
Does having rs5030866 mean my medications will not work?
Not necessarily. While this variant removes activity from one or both CYP2D6 gene copies, clinical outcomes depend on whether your medication relies on CYP2D6 for breakdown or activation, as well as the identity of your second allele.
How does this variant affect pain relievers like codeine?
Codeine requires functional CYP2D6 enzyme activity to convert into its active pain-relieving compound, morphine. Individuals who carry loss-of-function variants like *8 often experience inadequate pain relief from codeine or tramadol.
Can I adjust my drug doses if I test positive for rs5030866?
No, you should never alter your prescription regimens on your own based on genetic testing. Always discuss your pharmacogenomic test results with your prescribing doctor or pharmacist to determine whether standard monitoring or an alternative therapy is warranted.
Sources & further reading
Educational information only, last refreshed 9/6/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs5030866?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP2D6
Key defining missense polymorphism for the non-functional CYP2D6*10 allele conferring substantially reduced enzymatic clearance of numerous psychiatric drugs and analgesics.
Key defining pharmacogenomic single nucleotide variant determining metabolic clearance rate of psychotropic drugs prescribed for severe stress-related disorders.
Key defining single nucleotide polymorphism for the CYP2D6*21 non-functional allele (c.775delinsAA / p.Leu259fs), abolishing enzyme activity.
Defines the CYP2D6*41 core intron variant c.985+39G>A, a key CPIC-actionable decreased-function variant driving intermediate metabolizer status across Europe and the Middle East.
Defines the defining core missense variant c.506A>G (p.His169Arg) for the loss-of-function CYP2D6*14B allele associated with reduced or abolished CYP2D6 substrate clearance.
This variant defines the CYP2D6*4 non-functional allele, which causes impaired metabolism of numerous clinically prescribed medications including antidepressants, tamoxifen, and codeine.